Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2015 - 2026)

Spyre Therapeutics has reported Other Non-Current Liabilities for 12 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 92.18% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 92.18% YoY), and the FY2025 full-year result was $26.7 million, down 27.14% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.3 million, down from $26.7 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $164.7 million in Q2 2023, with the low at $8000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $35.5 million across 5 years, with a median of $31.4 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 96.12% — and 2024, when it jumped 74.77%.
• Spyre Therapeutics' Other Non-Current Liabilities stood at $8000.0 in 2022, then soared by 516275.0% to $41.3 million in 2023, then decreased by 11.35% to $36.6 million in 2024, then fell by 27.14% to $26.7 million in 2025, then tumbled by 95.16% to $1.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.3 million (Q1 2026), $26.7 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.